To view the entire topic, please log in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:
-- The first section of this topic is shown below --
*In clinical trials, prevalence of Q80K polymorphism observed in 30% patients infected with HCV genotype1a and only 0.5% in patients infected with HCV genotype 1b.
Simeprevir plus sofosbuvir +/- ribavirin is a recommended first line regimen for the treatment of HCV genotype 1a and 1b. NS3 Q80K polymorphism for genotype 1a did not significantly impact sustained virologic response to this regimen.
-- To view the remaining sections of this topic, please log in or purchase a subscription --
*In clinical trials, prevalence of Q80K polymorphism observed in 30% patients infected with HCV genotype1a and only 0.5% in patients infected with HCV genotype 1b.
Simeprevir plus sofosbuvir +/- ribavirin is a recommended first line regimen for the treatment of HCV genotype 1a and 1b. NS3 Q80K polymorphism for genotype 1a did not significantly impact sustained virologic response to this regimen.
There's more to see -- the rest of this entry is available only to subscribers.